ALLMedicine™ Adenoid Cystic Carcinoma Center

Aug 12th, 2022 - 68Ga-FAPI is a positron labeled inhibitor of fibroblast activating protein, which has been widely used in malignant tumor imaging in recent years. Adenoid cystic carcinoma (ACC) is a rare epithelial malignant tumor, which usually originates from s...

Aug 12th, 2022 - Adenoid cystic carcinoma (ACC) is a rare salivary cancer. The highest rates of disease recurrence are in patients with NOTCH pathway activation, reported in up to 20%. Novel drugs targeting NOTCH signaling are under investigation in the recurrent/...

Aug 10th, 2022 - Primary adenoid cystic carcinoma (ACC) of the trachea is a rare entity, with a 5-year survival between 50% and 80% for resectable cases and 30% in case of unresectable disease. We report a case of a primary ACC on a woman in her 70s that presented...

Aug 9th, 2022 - To investigate the prognosis and quality of life for primary malignant maxillary sinus tumors. This was a retrospective analysis. 164 patients diagnosed with primary malignant maxillary sinus tumors between 2005 and 2018 were recruited. Patients w...

Aug 8th, 2022 - No study has evaluated the impact of regimen on recurrence, metastasis and survival in patients with adenoid cystic carcinoma (ACC). The present study aimed to compare the efficacy of radioactive seed implantation and other regimens in treating AC...

Aug 12th, 2022 - 68Ga-FAPI is a positron labeled inhibitor of fibroblast activating protein, which has been widely used in malignant tumor imaging in recent years. Adenoid cystic carcinoma (ACC) is a rare epithelial malignant tumor, which usually originates from s...

Aug 8th, 2022 - ACC is a rare cancer of salivary glands and other glandular tissue. It is slow growing and is usually treated with surgery and radiation. However, this type of cancer tends to have a high rate of recurrence and metastatic spread, which develops ov...

Jul 28th, 2022 - This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational agent to learn whether it works in treating a specific disease. "Investigational" means that the drug is being studi...

Jul 27th, 2022 - The maximum tolerated dose (MTD) of E7389 liposomal formulation (E7389-LF) will be determined in the dose escalation part. Safety, pharmacokinetics (PK) and efficacy will be assessed using treatment regimen evaluated in dose escalation part in par...

Jun 23rd, 2022 - The purpose of this study is to see if the study drugs, lenvatinib and pembrolizumab, are effective in treating advanced Adenoid Cystic Carcinoma (ACC) or other salivary gland cancers that have come back and/or spread to other parts of the body. R...

Oct 6th, 2021 - New center offers unique treatment and research opportunities largely unavailable elsewhere Dana-Farber Cancer Institute has launched the Center for Salivary and Rare Head and Neck Cancers to treat patients with rare and occasionally aggressive c...

Apr 12th, 2021 - Certain histological subtypes of triple-negative breast cancer (TNBC) were more aggressive with worse treatment response and clinical course compared with others, researchers reported. A cohort study of 8,479 patients with rare breast cancers from...

Dec 20th, 2020 - Stuart J. Schnitt, MD All triple-negative breast cancers (TNBCs) are not created equal, and clinicians should consider their inherent heterogeneity during diagnosis and treatment planning, said Stuart J. Schnitt, MD, during a presentation at the ...

Nov 11th, 2020 - Great strides have been made with targeted approaches in patients with head and neck cancer, including those with rarer diseases like thyroid cancer and salivary gland cancers, due to a greater understanding of disease biology and genomics, accord...

Oct 20th, 2020 - The PLCOm2012 risk prediction model is a preferable lung cancer screening method for identifying African American ever-smokers over the current United States Preventive Services Task Force (USPSTF) lung cancer screening eligibility criteria, which...